BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

Collateral Therapeutics Incorporated

Collateral's initial non-surgical gene therapy products under investigation are designed to promote and enhance angiogenesis, a natural biological process which results in the growth of additional blood vessels, to increase levels of blood flow to oxygen-deprived tissues.

The Company's angiogenic products are administered using methods of gene therapy based on non-surgical adenoviral vector delivery of angiogenic genes. In addition to the Company's angiogenic product candidates, the Company is actively researching gene therapy products designed to increase responsiveness of the heart to adrenergic stimulation and to stimulate heart muscle regeneration.



The Company's lead product candidate, GENERX™ (Ad5-FGF4) is a non-surgical angiogenic gene therapy, which is being developed as a potential treatment for patients with stable exertional angina (chest pain) due to coronary artery disease (CAD).


Contact Details:
11622 El Camino Real
San Diego
ca
92130
United States of America
Tel:858.794.3400
Fax:858.794.3440
Email:info@collateralthx.com
WWW:

www.collateralthx.com/




Loading...

Recent Publications by Collateral Therapeutics Incorporated:

Intracoronary delivery of an adenovirus encoding fibroblast growth factor-4 in myocardial ischemia: effect of serum antibodies and previous exposure to adenovirus.
The presence of anti-adenoviral serotype 5 (Ad5) antibodies may limit the...
11th March, 2006
Collateral Therapeutics Inc., San Diego, CA 92130, USA. Hum Gene Ther. 2006 Feb;17(2):230-8.
DOI Direct Link
Controlled expression of cardiac-directed adenylylcyclase type VI provides increased contractile function.
OBJECTIVE: We have previously shown that cardiac-directed expression of...
18th December, 2002
Collateral Therapeutics Incorporated, San Diego, CA, USA. Cardiovasc Res. 2002 Nov;56(2):197-204.

BioNews Results for Collateral Therapeutics Incorporated:

Artes Medical Announces Plan for Nasdaq Listing Compliance and Agenda for Its Annual Meeting
Pharma Live:  Sep 3 2008 4:47PM Matching: collateral therapeutics
Lung cancer vaccine shows great promise
SignOn San Diego:  Aug 21 2008 2:21PM Matching: collateral therapeutics

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 273 times since April 2007, the link to the organisation's website has been followed 59 times

Recent Search Terms used to find this page: Collateral therapeutics | pericor therapeutics incorporation | collateral therapeutics | collateral therapeutics | collateral therapeutics | collateral therapeutics | Collateral Therapeutics | collateral therapeutics | .

Search for more companies in San Diego

Search for more companies in ca



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Collateral Therapeutics Incorporated
 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.